Advertisement
U.S. markets closed

Eloxx Pharmaceuticals, Inc. (ELOX)

Other OTC - Other OTC Delayed Price. Currency in USD
0.8700-0.0100 (-1.14%)
At close: 02:33PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8800
Open0.8950
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range0.8600 - 0.8950
52 Week Range0.4000 - 10.9000
Volume6,068
Avg. Volume19,848
Market Cap2.735M
Beta (5Y Monthly)2.76
PE Ratio (TTM)N/A
EPS (TTM)-8.8800
Earnings DateMar 29, 2024 - Apr 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ELOX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Eloxx Pharmaceuticals, Inc.
    Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more